Prosecution Insights
Prosecution Insights
Technology area: Computing & Software
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Gannex Pharma Co. Ltd. currently has 1 pending office action in the Computing & Software technology area. This single matter is assigned to 1 distinct examiner, STCLAIR, ANDREW D, who is also the busiest examiner for the portfolio. The concentration of the 1 pending office action under 1 distinct examiner means that the company's current prosecution results are entirely dependent on the review of this specific individual. This creates a highly focused environment for the company's intellectual property efforts.
The portfolio is limited to 1 distinct art unit, which is consistent with the single pending office action in Computing & Software. With STCLAIR, ANDREW D managing the 1 pending office action, there is no current diversification across different examiners or art units. For a practitioner, this means that the prosecution strategy for Gannex Pharma Co. Ltd. is unified and must be precisely calibrated to the expectations of the 1 distinct examiner. The outcome of this pending matter will define the company's current progress in the Computing & Software sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STCLAIR, ANDREW D | 1 | 60.2% | +25.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18357775 | PHARMACEUTICAL COMPOSITIONS, METHOD OF MAKING AND METHOD OF USING THEREOF | STCLAIR, ANDREW D | 475d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18357775 | PHARMACEUTICAL COMPOSITIONS, METHOD OF MAKING AND METHOD OF USING THEREOF | STCLAIR, ANDREW D | 475d overdue |
| Art Unit | Apps |
|---|---|
| 2178 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18357775 | PHARMACEUTICAL COMPOSITIONS, METHOD OF MAKING AND METHOD OF USING THEREOF | STCLAIR, ANDREW D | 2178 | §103§112 | Non-Final OA | 475d overdue | Pending | Jul 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial